参考文献
[1] Blundell J,Finlayson G,Axelsen M,et al.Effects of once ‐ weekly semaglutideon appetite,energy intake,control of eating,food preference and body weight in subjects with obesity[J]. Diabetes,Obesity and Metabolism,2017,19( 9) : 1242-1251
[2] 霍艳超,贾琼,王真真等.司美格鲁肽用于超重人群慢性体重管理的研究进展[J].中国药物评价,2023, 40(02):163-166.
[3]Jastreboff AM, Kushner RF. New Frontiers inObesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-BasedTherapeutics. Annu Rev Med. 2023 Jan27;74:125-139.doi:10.1146/annurev-med-043021
-014919. PMID: 36706749.
[4]中国居民肥胖防治专家共识[J].西安交通大学学报(医学版),2022,43(04):619-631.
[5]纪立农.胰高血糖素样肽1受体激动剂周制剂中国证据与专家指导建议[J].中国糖尿病杂志, 2022, 30(6):7.
[6]吕美锋,张雅慧,冷冰等.胰高血糖素样肽-1受体激动剂在肥胖治疗中的研究进展[J].中国医院药学杂志,2024,44(04):467-480+484.DOI:10.13286/j.1001-5213.2024.04.17.